Brammer Bio News

Amicus Therapeutics and Brammer Bio, a part of Thermo Fisher Scientific, Enter Strategic Gene Therapy Development and Manufacturing Collaboration

Amicus Therapeutics, Inc. (NASDAQ: FOLD) has entered into a strategic manufacturing collaboration with Thermo Fisher Scientific. Thermo Fisher, a best-in-class contract development and manufacturing organization (CDMO) with late-stage clinical and commercial-scale capabilities provides Amicus with immediate clinical and commercial manufacturing capabilities and capacity for the Amicus intrathecal AAV Batten disease gene therapy programs.

Read more . . . 

Brammer Bio Supports Rare Disease Day

Brammer Bio, a best-in-class viral vector contract development and manufacturing organization (CDMO) for cell and gene therapy companies, supports Rare Disease Day in raising awareness about rare diseases and their impact on patients' lives. Rare Disease Day, held on the last day of February each year, is inspired to encourage our policy makers, public authorities, industry colleagues, researchers, and health professionals in efforts to address the unmet medical needs of patients with rare diseases. For more information, please visit www.rarediseaseday.org. Brammer is a sponsor and will participate in the MassBio Forum event in Boston, MA.

Read more . . . 

DPS Group Selected to Design Two cGMP Commercial Manufacturing Facilities for Brammer Bio

DPS Group​, a privately-owned, global engineering, procurement, construction management and validation (EPCMV) firm serving high-tech process industries, announced today that it has been selected to design two cGMP manufacturing facilities for Brammer Bio, an industry leading viral vector contract development and manufacturing organization (CDMO). 

Read more . . . 

Brammer Bolsters Leadership Team and Announces Chief Quality Officer

Brammer Bio, a best-in-class viral vector contract development and manufacturing organization (CDMO) for companies developing gene-modified cell therapies and in vivo gene therapies, announces recent leadership appointments to support the growth of the organization.

Read more . . . 

Brammer Bio Now Up to 240 Employees in Florida, Continues Expansion

Brammer Bio, a contract development and manufacturing organization (CDMO) serving companies seeking to develop and commercialize gene therapies, has expanded its Progress Park location dramatically over the past two years.

Read more . . . 

Voyager Therapeutics Enters into Strategic Manufacturing Collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies

 

Voyager Therapeutics, a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced that it has entered into collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies to further expand Voyager's manufacturing capabilities to support the development of its gene therapy programs.

Read more . . .

 

 

 

 

 

Brammer Bio is Named Manufacturing Company of the Year

 

Brammer Bio was recognized by the Greater Gainesville Chamber of Commerce as the Manufacturing Company of the Year at its recent 2018 Business of the Year awards program. Brammer was also named one of the top-three finalists for the BioScience Company of the Year award.

Read more . . .

 

 

 

Brammer Bio Announces Progress on $200 Million Program to Advance Gene Therapies
 

Brammer Bio announces that a three-year, $200 million investment program is on track to establish over 30 suites for clinical and commercial viral vector supply for a broad pipeline of advanced gene therapies and gene-modified cell therapies.

Read more . . .


 

Brammer Bio Featured on WCJB TV20 Tech Tuesday Program

Brammer Bio was featured on Tech Tuesday, a weekly program on Alachua County, Fla. ABC affiliate WCJB TV20 that features technology based businesses. The program includes interviews with Chief Scientific Officer Richard Snyder, Vice President and Site Head Larry Pitcher and Associate Director of Process Development and Quality Control Sushma Ogram.

 

Read more . . .

 

 

 

 

 

Sarepta Therapeutics Enters Into Long-term Strategic Manufacturing Partnership with Brammer Bio to Support Gene Therapy Development and Commercial Supply

 

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, announced  today that it has entered into a long-term strategic manufacturing partnership with Brammer Bio, which will provide Sarepta access to clinical and commercial manufacturing capacity for its micro-dystrophin Duchenne muscular dystrophy (DMD) gene therapy program and a manufacturing platform for future gene therapy programs, such as Limb girdle muscular dystrophy (LGMD).

Read more . . .

 

 

 

Brammer Bio Supports Rare Disease Day 2018

 

Brammer Bio supports Rare Disease Day in raising awareness about rare diseases and their impact on patients' lives. Rare Disease Day is inspired to encourage our policy makers, public authorities, industry colleagues, researchers, and health professionals in efforts to address the unmet medical needs of patients with rare diseases.

Read more . . .

 

Brammer Bio Launches Gene Therapy Product Manufacturing Operations in Massachusetts

Brammer announces its completion of renovations and launch of its late-stage clinical capacity and commercial-ready cGMP manufacturing site in Cambridge, Massachusetts for gene therapy products.

Read more . . .

 

 

 

 


Abeona Therapeutics and Brammer Bio Announce Collaboration for Commercial Translation

of ABO-102

Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, announced today an update on the Company’s manufacturing strategy and plans for ABO-102, including strategic manufacturing commitments with Brammer Bio for commercial translation.

Read more . . .

 

Brammer Bio Completes Expansion of Cell and Gene Therapy Clinical Manufacturing Facilities in Florida

Brammer announces completion of its clinical capacity expansion in Alachua, Florida, doubling the company's early phase manufacturing capacity to support clients' Phase I/II cell and gene therapy clinical trials. 

Read more . . .

 

 

Brammer Bio Appoints Leading Commercial Manufacturing and Gene Therapy Expert as
Chief Manufacturing Officer

Mr. Christopher Murphy joins Brammer as chief manufacturing officer. Chris brings a wealth of commercial biologics manufacturing, viral vector development, and clinical manufacturing experience to the company's commercial gene therapy manufacturing operations.

Read more . . .

 

Lysogene Selects Brammer Bio to Produce GM1 Gangliosidosis Gene Therapy Product

Lysogene, a leading, biopharmaceutical company pioneering gene therapy technologies to treat central nervous system diseases, today announced that it has entered into a strategic manufacturing agreement with Brammer Bio.

Read more . . .

Brammer Bio Announces Major Milestone in Establishing Commercial-ready Gene Therapy Supply for the Industry

Brammer Bio (“Brammer”), a cell and gene therapy contract development and manufacturing organization (CDMO), today announced that it is on track to complete the establishment of commercial-ready gene therapy capacity in Cambridge, MA.

Read more . . .

Brammer Bio opens new cell and gene therapy manufacturing facility

by Melissa Fassbender

Brammer Bio, the best-in-class cell and gene therapy contract development and manufacturing organization, is proud to announce plans to build-out a 50,000 sq. ft. facility dedicated to late phase development, including Phase III and commercial production of viral vector-based and cell-based
advanced therapies.

Read more . . .

Sept 28, 2017

Sept 18, 2017

May 24, 2017

May 9, 2017

June 8, 2016

Thermo Fisher Scientific Completes Acquisition of Brammer Bio

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that it has completed its previously announced acquisition of Brammer Bio, a leader in viral vector manufacturing for gene and cell therapies, for approximately $1.7 billion in cash.  The completion of the transaction follows the receipt of all required regulatory approvals.

Read more . . . 

Freeline Secures Long-Term Commercial Manufacturing Capacity at Brammer Bio for Haemophilia B Gene Therapy

Freeline announced today it has signed a multi-year agreement with Brammer Bio, a leading gene therapy contract development and manufacturing organisation, to secure a dedicated AAV manufacturing suite in Brammer’s state-of-the-art Cambridge, MA facility. 

Read more . . . 

Sangamo Announces Agreement Securing Access to Large-Scale, Commercial-Grade Manufacturing Capacity at Brammer Bio

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced it has signed an option agreement with Brammer Bio, a gene therapy contract development and manufacturing organization, to secure access to large-scale AAV manufacturing. Additionally, at Sangamo's new facilities in Brisbane, California, construction is underway of a Phase 1/2 cGMP manufacturing facility, which is expected to be operational in 2020.

Read more . . . 

Thermo Fisher Scientific to Acquire Brammer Bio, a Leader in Viral Vector Manufacturing

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Brammer Bio, a leader in viral vector manufacturing for gene and cell therapies, today announced they have entered into a definitive agreement under which Thermo Fisher will acquire Brammer Bio for approximately $1.7 billion in cash. Brammer Bio is a leading viral vector contract development and manufacturing organization (CDMO), enabling biopharma customers to deliver breakthrough medicines to patients by unleashing the potential of gene therapies and gene-modified cell therapies. The business has nearly 600 employees at primary locations in Massachusetts and Florida.

Read more . . . 

Brammer Bio Supports Rare Disease Day

Brammer Bio, a best-in-class viral vector contract development and manufacturing organization (CDMO) for cell and gene therapy companies, supports Rare Disease Day in raising awareness about rare diseases and their impact on patients' lives. Rare Disease Day, held on the last day of February each year, is inspired to encourage our policy makers, public authorities, industry colleagues, researchers, and health professionals in efforts to address the unmet medical needs of patients with rare diseases. For more information, please visit www.rarediseaseday.org. Brammer is a sponsor and will participate in the MassBio Forum event in Boston, MA.

Read more . . . 

DPS Group Selected to Design Two cGMP Commercial Manufacturing Facilities for Brammer Bio

DPS Group​, a privately-owned, global engineering, procurement, construction management and validation (EPCMV) firm serving high-tech process industries, announced today that it has been selected to design two cGMP manufacturing facilities for Brammer Bio, an industry leading viral vector contract development and manufacturing organization (CDMO). 

Read more . . . 

Brammer Bolsters Leadership Team and Announces Chief Quality Officer

Brammer Bio, a best-in-class viral vector contract development and manufacturing organization (CDMO) for companies developing gene-modified cell therapies and in vivo gene therapies, announces recent leadership appointments to support the growth of the organization.

Read more . . . 

Brammer Bio Now Up to 240 Employees in Florida, Continues Expansion

Brammer Bio, a contract development and manufacturing organization (CDMO) serving companies seeking to develop and commercialize gene therapies, has expanded its Progress Park location dramatically over the past two years.

Read more . . . 

Voyager Therapeutics Enters into Strategic Manufacturing Collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies

 

Voyager Therapeutics, a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced that it has entered into collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies to further expand Voyager's manufacturing capabilities to support the development of its gene therapy programs.

Read more . . .

 

 

 

 

 

Brammer Bio is Named Manufacturing Company of the Year

 

Brammer Bio was recognized by the Greater Gainesville Chamber of Commerce as the Manufacturing Company of the Year at its recent 2018 Business of the Year awards program. Brammer was also named one of the top-three finalists for the BioScience Company of the Year award.

Read more . . .

 

 

 

Brammer Bio Announces Progress on $200 Million Program to Advance Gene Therapies
 

Brammer Bio announces that a three-year, $200 million investment program is on track to establish over 30 suites for clinical and commercial viral vector supply for a broad pipeline of advanced gene therapies and gene-modified cell therapies.

Read more . . .


 

Brammer Bio Featured on WCJB TV20 Tech Tuesday Program

Brammer Bio was featured on Tech Tuesday, a weekly program on Alachua County, Fla. ABC affiliate WCJB TV20 that features technology based businesses. The program includes interviews with Chief Scientific Officer Richard Snyder, Vice President and Site Head Larry Pitcher and Associate Director of Process Development and Quality Control Sushma Ogram.

 

Read more . . .

 

 

 

 

 

Sarepta Therapeutics Enters Into Long-term Strategic Manufacturing Partnership with Brammer Bio to Support Gene Therapy Development and Commercial Supply

 

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, announced  today that it has entered into a long-term strategic manufacturing partnership with Brammer Bio, which will provide Sarepta access to clinical and commercial manufacturing capacity for its micro-dystrophin Duchenne muscular dystrophy (DMD) gene therapy program and a manufacturing platform for future gene therapy programs, such as Limb girdle muscular dystrophy (LGMD).

Read more . . .

 

 

 

Brammer Bio Supports Rare Disease Day 2018

 

Brammer Bio supports Rare Disease Day in raising awareness about rare diseases and their impact on patients' lives. Rare Disease Day is inspired to encourage our policy makers, public authorities, industry colleagues, researchers, and health professionals in efforts to address the unmet medical needs of patients with rare diseases.

Read more . . .

 

Brammer Bio Launches Gene Therapy Product Manufacturing Operations in Massachusetts

Brammer announces its completion of renovations and launch of its late-stage clinical capacity and commercial-ready cGMP manufacturing site in Cambridge, Massachusetts for gene therapy products.

Read more . . .

 

 

 

 


Abeona Therapeutics and Brammer Bio Announce Collaboration for Commercial Translation

of ABO-102

Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell therapies for life-threatening rare diseases, announced today an update on the Company’s manufacturing strategy and plans for ABO-102, including strategic manufacturing commitments with Brammer Bio for commercial translation.

Read more . . .

 

Brammer Bio Completes Expansion of Cell and Gene Therapy Clinical Manufacturing Facilities in Florida

Brammer announces completion of its clinical capacity expansion in Alachua, Florida, doubling the company's early phase manufacturing capacity to support clients' Phase I/II cell and gene therapy clinical trials. 

Read more . . .

 

 

Brammer Bio Appoints Leading Commercial Manufacturing and Gene Therapy Expert as
Chief Manufacturing Officer

Mr. Christopher Murphy joins Brammer as chief manufacturing officer. Chris brings a wealth of commercial biologics manufacturing, viral vector development, and clinical manufacturing experience to the company's commercial gene therapy manufacturing operations.

Read more . . .

 

Lysogene Selects Brammer Bio to Produce GM1 Gangliosidosis Gene Therapy Product

Lysogene, a leading, biopharmaceutical company pioneering gene therapy technologies to treat central nervous system diseases, today announced that it has entered into a strategic manufacturing agreement with Brammer Bio.

Read more . . .

Brammer Bio Announces Major Milestone in Establishing Commercial-ready Gene Therapy Supply for the Industry

Brammer Bio (“Brammer”), a cell and gene therapy contract development and manufacturing organization (CDMO), today announced that it is on track to complete the establishment of commercial-ready gene therapy capacity in Cambridge, MA.

Read more . . .

Brammer Bio opens new cell and gene therapy manufacturing facility

by Melissa Fassbender

Brammer Bio, the best-in-class cell and gene therapy contract development and manufacturing organization, is proud to announce plans to build-out a 50,000 sq. ft. facility dedicated to late phase development, including Phase III and commercial production of viral vector-based and cell-based
advanced therapies.

Read more . . .

Sept 28, 2017

Sept 18, 2017

May 24, 2017

May 9, 2017

June 8, 2016

No Logo Banner_Rev4.15.1 (1).png